Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs
Author(s)
Strand, Vibeke
Van den Bosch, Filip
Ranza, Roberto
Leung, Ying Ying
Drescher, Edith
Lertratanakul, Apinya
Lippe, Ralph
Saffore, Christopher
Zueger, Patrick
Nash, Peter
Griffith University Author(s)
Year published
2021
Metadata
Show full item recordAbstract
Aim: Patient-reported outcomes (PROs) are an important component in the evaluation of efficacy for a new therapy. This post hoc analysis evaluated the impact of Upadactinib (UPA), a selective Janus kinase inhibitor vs placebo (PBO) on PROs in patients with active PsA and an inadequate response to biologic DMARDs (bDMARD-IR).
Methods: Patients in SELECT-PsA 2 (NCT03104374), a Phase 3, randomized, PBO-controlled trial, received UPA 15 mg or UPA 30 mg once daily or PBO for 24 weeks, with the primary endpoint assessment at Week 12. The following PROs were assessed: Patient Global Assessment of Disease Activity (PtGA), Patient's ...
View more >Aim: Patient-reported outcomes (PROs) are an important component in the evaluation of efficacy for a new therapy. This post hoc analysis evaluated the impact of Upadactinib (UPA), a selective Janus kinase inhibitor vs placebo (PBO) on PROs in patients with active PsA and an inadequate response to biologic DMARDs (bDMARD-IR). Methods: Patients in SELECT-PsA 2 (NCT03104374), a Phase 3, randomized, PBO-controlled trial, received UPA 15 mg or UPA 30 mg once daily or PBO for 24 weeks, with the primary endpoint assessment at Week 12. The following PROs were assessed: Patient Global Assessment of Disease Activity (PtGA), Patient's Assessment of Pain, HAQ-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue, 36-Item Short-Form Health Survey (SF-36), EQ-5D-5L, Self-Assessment of Psoriasis Symptoms (SAPS), Work Productivity and Activity Impairment, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and morning stiffness (items 5 and 6 from the BASDAI). Results: Data from 641 patients (UPA 15 mg: 211; UPA 30 mg: 218; PBO: 212) were analyzed. Significant improvements from BL to Week 12 were reported with both doses of UPA vs PBO across all PROs, including all SF-36 domains. Significantly greater proportions of patients receiving either dose of UPA vs PBO reported improvements ≥ MCID as early as Week 2 (the first post-BL visit) in PtGA, pain, and HAQ-DI. Compared with PBO at Week 12, a significantly greater proportion of patients receiving either dose of UPA reported improvements ≥ MCID across all PROs except SF-36 mental component summary (UPA 30 mg). Improvements were maintained or further improved through Week 24. Conclusion: Among bDMARD-IR patients with active PsA, treatment with UPA 15 mg or 30 mg once daily for 12 weeks resulted in clinically meaningful improvements in PROs, which were maintained or further improved through 24 weeks.
View less >
View more >Aim: Patient-reported outcomes (PROs) are an important component in the evaluation of efficacy for a new therapy. This post hoc analysis evaluated the impact of Upadactinib (UPA), a selective Janus kinase inhibitor vs placebo (PBO) on PROs in patients with active PsA and an inadequate response to biologic DMARDs (bDMARD-IR). Methods: Patients in SELECT-PsA 2 (NCT03104374), a Phase 3, randomized, PBO-controlled trial, received UPA 15 mg or UPA 30 mg once daily or PBO for 24 weeks, with the primary endpoint assessment at Week 12. The following PROs were assessed: Patient Global Assessment of Disease Activity (PtGA), Patient's Assessment of Pain, HAQ-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue, 36-Item Short-Form Health Survey (SF-36), EQ-5D-5L, Self-Assessment of Psoriasis Symptoms (SAPS), Work Productivity and Activity Impairment, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and morning stiffness (items 5 and 6 from the BASDAI). Results: Data from 641 patients (UPA 15 mg: 211; UPA 30 mg: 218; PBO: 212) were analyzed. Significant improvements from BL to Week 12 were reported with both doses of UPA vs PBO across all PROs, including all SF-36 domains. Significantly greater proportions of patients receiving either dose of UPA vs PBO reported improvements ≥ MCID as early as Week 2 (the first post-BL visit) in PtGA, pain, and HAQ-DI. Compared with PBO at Week 12, a significantly greater proportion of patients receiving either dose of UPA reported improvements ≥ MCID across all PROs except SF-36 mental component summary (UPA 30 mg). Improvements were maintained or further improved through Week 24. Conclusion: Among bDMARD-IR patients with active PsA, treatment with UPA 15 mg or 30 mg once daily for 12 weeks resulted in clinically meaningful improvements in PROs, which were maintained or further improved through 24 weeks.
View less >
Conference Title
Internal Medicine Journal
Volume
51
Issue
S2
Publisher URI
Subject
Cardiovascular medicine and haematology
Clinical sciences
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine